Prevalence of reduced drug susceptibility in treatment-naive patients in the UK. 13th International Drug Resistance Workshop, 8-12 June 2004.. 2004.
Time trends in HIV drug resistance in ART-experienced patients in the UK: impact of improved treatments and boosted protease inhibitors. 13th Annual Conference of the British HIV Association, 25-28 April 2007.. 2007.
Population trends in the prevalence and patterns of protease resistance related to exposure to unboosted and boosted protease inhibitors. Antivir Ther. 13:771-7.. 2008.
Patterns of thymidine analogue mutations (TAMS) in samples sent for routine HIV drug resistance testing. 14th International HIV Drug Resistance Workshop, 7-11 June 2005.. 2005.
Genotypic resistance testing in routine clinical care. Curr Opin HIV AIDS. 6:251-7.. 2011.
Impact of HIV-1 subtype on genotypic resistance to protease inhibitors in the United Kingdom. 13th Conference on Retroviruses and Opportunistic Infections, 5-8 February 2006.. 2006.
HIV-1 drug resistance mutations emerging on darunavir therapy in PI-naive and -experienced patients in the UK. J Antimicrob Chemother. 71(12). 2016.
Mapping the circulation of HIV-1 recombinants among MSM. 18th Conference on Retroviruses and Opportunistic Infections, 27 Feb - 2 Mar 2011.. 2011.
Novel HIV-1 recombinants spreading across multiple risk groups in the United Kingdom: the identification and phylogeography of Circulating Recombinant Form (CRF) 50_A1D. PLoS One. 9:e83337.. 2014.
Transmission dynamics of CRF50_A1D across most at risk communities in the UK. 19th International HIV Dynamics & Evolution Conference, 25-28 April 2012.. 2012.
Epidemiology of non-B clade forms of HIV-1 in MSM in the UK. 13th Annual Conference of the British HIV Association, 25-28 April 2007.. 2007.
Virological outcomes of boosted protease inhibitor-based first-line ART in subjects harbouring thymidine analogue-associated mutations as the sole form of transmitted drug resistance.. J Antimicrob Chemother.. 2018.
Effect of HIV-1 subtype on virologic and immunologic response to starting highly active antiretroviral therapy. Clin Infect Dis. 48:1296-305.. 2009.
The H208Y mutation in reverse transcriptase is significantly associated with NRTI exposure, M184V and TAM mutation pathways. 15th International HIV Drug Resistance Workshop, 13-17 June 2006.. 2006.
Mutations at reverse transcriptase (RT) codons G196, Q207, H208, R211 and I214 are associated with drug experience and specific RT mutation patterns. 14th International HIV Drug Resistance Workshop, 7-11 June 2005.. 2005.
Impact of Transmitted Thymidine Analogue Mutations on Responses to First-Line ART. Conference on Retroviruses and Opportunistic Infections (CROI) 2016.. 2016.
Prevalence and patterns of antiretroviral drug resistance at low plasma HIV RNA load levels. 17th International HIV Drug Resistance Workshop, 10-14 June 2008.. 2008.
Detection of clinically relevant antiretroviral drug resistance mutations among treated patients undergoing testing at low levels of viraemia. 18th International HIV Drug Resistance Workshop, June 2009.. 2009.
Impact of Transmitted Thymidine Analogue Mutations on Responses to First-Line ART. International HIV Drug Resistance Workshop 2016.. 2016.